Apriori Bio Announces Collaboration with the Francis Crick Institute
Apriori to leverage foundational insights from the Crick's Legacy Study to further validate Octavia™ platform's ability to predict viral evolution and vaccine performance CAMBRIDGE, Mass., Aug. 12,...
What risks remain regarding the successful validation of the Octavia™ platform and its translation into commercial vaccine performance?
Are there any contingent financing or milestone payments tied to the outcomes of the collaboration that could affect the balance sheet?
How might this news influence analyst coverage and target price revisions for Apriori Bio?
14 days ago